Search results
Results from the WOW.Com Content Network
Rubella vaccine is a vaccine used to prevent rubella. [1] Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of rubella or congenital rubella syndrome .
Four out of six WHO regions have goals to eliminate rubella, with the WHO recommending using existing measles programmes for vaccination with combined vaccines such as the MMR vaccine. The number of reported cases dropped from 670,000 in the year 2000 to below 15,000 in 2018, and the global coverage of rubella vaccination was estimated at 69% ...
Rubella, also known as German measles or three-day measles, [6] is an infection caused by the rubella virus. [3] This disease is often mild, with half of people not realizing that they are infected. [ 1 ] [ 7 ] A rash may start around two weeks after exposure and last for three days. [ 1 ]
Rubella virus, scientific name Rubivirus rubellae, is a member of the genus Rubivirus and belongs to the family of Matonaviridae, whose members commonly have a genome of single-stranded RNA of positive polarity which is enclosed by an icosahedral capsid.
The 1962–1965 rubella epidemic was an outbreak of rubella across Europe and the United States. [ 1 ] [ 2 ] The Rubella virus, also known as the German measles, is a single-stranded RNA virus from the family Togaviridae and genus Rubivirus . [ 3 ]
The number of measles cases around the world nearly doubled from 2022 to 2023, researchers say, presenting a challenge to efforts to achieve and maintain elimination status in many countries.
This is an accepted version of this page This is the latest accepted revision, reviewed on 20 December 2024. Combined vaccine against measles, mumps, and rubella Pharmaceutical compound MMR vaccine MMR vaccine Combination of Measles vaccine Vaccine Mumps vaccine Vaccine Rubella vaccine Vaccine Clinical data Trade names M-M-R II, Priorix, Tresivac, others Other names MPR vaccine AHFS / Drugs ...
The agency's decision has no impact on the approved indication for the vaccine in the U.S. for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of ...